RFA-HS-23-012: Implementing and Evaluating New Models for Delivering Comprehensive, Coordinated, Person-Centered Care to People with Long COVID (U18)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Agency for Health Care Research and Quality notices from 2023.
Agency for Health Care Research and Quality offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on June 13, 2023.
From the official notice on Grants.gov, last changed April 3, 2023. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | April 3, 2023 |
|---|---|
| Deadline | June 13, 2023 |
| Archived by Grants.gov | July 19, 2023 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Is this a realistic fit?
- Most of the program's money (69% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this Notice of Funding Opportunity (NOFO) is to expand access to comprehensive, coordinated, and person-centered care for people with Long COVID, particularly underserved, rural, vulnerable, or minority populations that are disproportionately impacted by the effects of Long COVID. This NOFO will fund up to nine multidisciplinary Long COVID clinics to (1) develop and implement new or improved care delivery models, (2) provide services to more people with Long COVID, (3) expand services offered, (4) strengthen care coordination, (5) implement and share best practices for Long COVID management, (6) support the primary care community in Long COVID education and management, (7) evaluate project success, and (8) disseminate project findings
Who has won Research on Healthcare Costs, Quality and Outcomes grants before
From fiscal 2021 to 2025, Research on Healthcare Costs, Quality and Outcomes (93.226) awarded $686 million across 791 grant awards, an average of $867,535 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Regents of the University of Michigan | Michigan | 45 | $46.0 million |
| The Johns Hopkins University | Maryland | 25 | $23.6 million |
| Brigham & Womens Hospital Inc | Massachusetts | 16 | $22.2 million |
| The Regents of the University of California, San Francisco | California | 22 | $19.4 million |
| The Regents of the University of Colorado | Colorado | 23 | $18.5 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-HS-23-012 still open?
No. It closed on June 13, 2023.
Who can apply for Implementing and Evaluating New Models for Delivering Comprehensive, Coordinated, Person-Centered Care to People with Long COVID (U18)?
Agency for Health Care Research and Quality accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Implementing and Evaluating New Models for Delivering Comprehensive, Coordinated, Person-Centered Care to People with Long COVID (U18)?
Closed June 13, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has won Research on Healthcare Costs, Quality and Outcomes grants before?
The largest recipients over five fiscal years were Regents of the University of Michigan, The Johns Hopkins University, Brigham & Womens Hospital Inc. The program made 791 awards worth $686 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)